Interpace Biosciences (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics.

Our Interpace Diagnostics business unit provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services, including such widely respected tests as PancraGen®, ThyGeNext®, ThyraMir®, RespriDX® and BarreGen®.

Our Interpace Pharma Solutions business supports clinical trials by providing lab testing, data management, project management, and biorepository services to biopharmaceutical companies, enabling them to effectively integrate pharmacogenomics into their drug development and clinical trial programs to deliver safer, more effective drugs to market faster.